Loading
Loading
Regenerative & Anti-Aging · 10mg
Janoshik-tested · 10 vials per kit
FOXO4-DRI is a synthetic retro-inverso peptide studied in preclinical research for its senolytic properties, selectively clearing senescent cells. Research has examined its potential to block the FOXO4-p53 interaction and induce apoptosis of senescent cells while preserving healthy cell populations. Studies have explored applications in anti-aging, tissue microenvironment restoration, and neurodegenerative disease models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
FOXO4-DRI
FOXO4-DRI is a D-retro-inverso (DRI) peptide designed to disrupt the FOXO4:p53 protein-protein interaction that keeps senescent cells alive. Published by Baar et al. in Cell (2017), it represents one of the first rationally designed senolytics — compounds that selectively eliminate senescent cells while sparing healthy cells. The DRI modification (D-amino acids in reverse sequence) confers protease resistance and membrane penetration.
In senescent cells, the transcription factor FOXO4 forms a complex with p53 at the nuclear envelope, sequestering p53 away from mitochondria and preventing it from triggering intrinsic apoptosis. Senescent cells thereby persist in a pro-survival state despite accumulating damage. FOXO4-DRI disrupts this FOXO4:p53 interaction, releasing p53 to translocate to mitochondria and trigger BAX/BAK-mediated apoptosis — specifically in senescent cells. Non-senescent cells, lacking this FOXO4-p53 survival complex, are largely unaffected.
The original Baar et al. mouse study demonstrated that FOXO4-DRI selectively eliminated p21-high/p16-high senescent cells in naturally aged, fast-aged (XPD mutant), and chemotherapy-treated mice — restoring physical fitness, renal function, and fur density. Subsequent research has examined FOXO4-DRI in pulmonary fibrosis, cancer-therapy-induced senescence, and liver fibrosis models.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
